Xceed Molecular is working to exceed the expectations of researchers performing gene expression tests. The company's flow-thru chip technology allows biotechnology and pharmaceutical companies to conduct genetic screening research. Its Ziplex system is used for automated gene expression analysis. Other products include assay reagent kits, sample preparation reagents, and its TipChip disposable microarrays. The company also produces chips to detect specific diseases and is working to speed up the time needed to process samples. Xceed Molecular, which was established in 2001, has facilities in Canada and the US.

Essential Nutrition Ltd. was founded in 1989. Essential Nutrition offers research, testing, and manufacturing services to drug companies. The UK-based firm estimates its manufacturing capacity to be up to 8.5 million tablets per day. The company also produces its own brand of health food supplements which it markets online. It partners with various agronomy firms to determine optimum location and growth cycles for its herbal medicine crops, and it has developed nutritional research with universities throughout the UK and US. Essential Nutrition is family owned and operated.

Ricerca Biosciences LLC company provides one stop shopping of pharmacology and toxicology, medicinal chemistry, drug substance synthesis, and preclinical and clinical development for small to medium pharmaceutical companies looking to bring drugs to market. The contract research organization (CRO) also offers regulatory filing and report writing services. Ricerca Biosciences provides expanded services through partnerships with companies such as Bicoll Group, Latitude Pharmaceuticals, and Xcelience Formulation Development.

XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California. XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on three approved products: RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis; LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA, which is approved in the U.S. and Switzerland for the treatment of Crohn's disease. Its products under development include XOMA 052, a monoclonal antibody for the treatment of Type 2 diabetes, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and gout, which is in Phase 1 clinical studies; and XOMA 3AB, a biodefense anti-botulism antibody for the treatment of botulism poisoning. The company's developing products also include HCD122, a human anti-CD40 antagonist antibody for the treatment for B-cell mediated diseases, including malignancies and autoimmune diseases in Phase 1 and Phase 2 clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Genentech, Inc.; UCB Celltech; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited.

ASI Technology Corporation was incorporated in 1931 and is based in Henderson, Nevada. ASI Technology Corporation, together with its subsidiaries, operates as a specialty finance company. The company offers commercial and venture capital loans, as well as provides direct finance leasing services. It also focuses on the development of plasma technology for sterilization and decontamination. The company's patented method uses low voltage to produce high volumes of atmospheric pressure plasma, also known as room temperature or cold plasma.

Dechra lies down with dogs ... and cats and birds and horses too. Dechra Pharmaceuticals lays claim to being the only listed pharmaceutical company that makes most of its income from the animal health care market. The company manufactures and distributes veterinary pharmaceutical products and supplies internationally, mainly in the US and the UK. Its network of subsidiaries includes suppliers National Veterinary Services and Dechra Veterinary Products, manufacturer Dales Pharmaceuticals, and development companies North Western Laboratories and Cambridge Specialist Laboratory Services.

Rubicon Genomics, Inc. was founded in 2000 and is based in Ann Arbor, Michigan. Rubicon Genomics, Inc. engages in the development and commercialization of pre-analytical and analytical kits and licenses to improve genetic, epigenetic, and expression analysis in research, diagnostic, and other clinical applications. It offers GenomePlex whole genome amplification platform, a research and diagnostic pre-analytical tool to amplify and standardize DNA for genetic analysis; TransPlex whole transcriptome amplification platform, which amplifies and standardizes RNA sequences for expression analysis; and MethylPlex platform, which amplifies and standardizes the methylated portion of DNA for methylation analysis. The company also provides kits for research and diagnostics applications; contract services to biotech, pharma, and diagnostic companies and institutions; OEM reagents for diagnostic manufacturing; partnerships to develop and commercialize cancer biomarkers and tests; out-licenses for cancer biomarkers; and out-licenses for kits and processes. In addition, it offers fee-for-service products, including whole genome amplification services, single-cell whole genome amplification services, whole transcriptome amplification services, and methylated DNA amplification and analysis services. The company serves pharmaceutical, biotechnology, diagnostic, government, academic, and research institutions.

Hybrigenics wants to open a new pathway towards the fight against cancer. Established in 1997, the drug discovery company zeroes in on new drug targets and therapeutic biological components with the help of its computer programs involving protein sequencing and other high tech chemical screening techniques. What separates it from other drug researching companies is its Laboratory Information Management System (LIMS), a product that commercializes its library screening and navigating capabilities regarding DNA and other related biological sequencing. With its headquarters in Paris, Hybrigenics also owns Semaia BV, a subsidiary located in the Netherlands, and an additional office in the US.

NitroMed, Inc. company has developed a technique to enhance nitric oxide and add it to drugs to improve their efficiency. Nitric oxide is formed in the body and plays a role in relaxing blood vessels, making it harder for blood platelets to stick to blood vessel walls, and thereby reducing the obstructions that lead to stroke. Its sole product, BiDil, has FDA approval and is specifically indicated for heart disease in self-identified African-Americans, a group that suffers from the disease at a higher rate than other ethnicities. NitroMed was acquired by health care investment group Deerfield Capital Management in 2009.

Pharmavite's Nature Made brand of vitamins, mineral supplements, and herbal remedies are sold through major mass retailers and drugstore chains. Like all successful supplement makers, Pharmavite's product lines shift and adapt and new product development is key. It has entered the snack food segment with its SOYJOY nutrition bars and manufactures vitamins under the Olay brand. Pharmavite was founded in 1971 and acquired by Otsuka Pharmaceutical in 1989. Otsuka has since introduced the Nature Made vitamin brand to Japan. Pharmavite manufactures all of its products at its facilities in California.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.